The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer Centre

Beth Russell; Charlotte Moss; Eirini Tsotra; Charalampos Gousis; Debra Josephs; Deborah Enting; Christina Karampera; Muhammad Khan; Jose Roca; Ailsa Sita-Lumsden; Kasia Owczarczyk; Harriet Wylie; Anna Haire; Daniel Smith; Kamarul Zaki; Angela Swampillai; Mary Lei; Vishal Manik; Vasiliki Michalarea; Rebecca Kristeleit; Anca Mera; Elinor Sawyer; Lucy Flanders; Irene De Francesco; Sophie Papa; Paul Ross; James Spicer; Bill Dann; Vikash Jogia; Nisha Shaunak; Hartmut Kristeleit; Anne Rigg; Ana Montes; Mieke Van Hemelrijck; Saoirse Dolly

doi:10.3390/cancers14020266

The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer Centre

Beth Russell^*, Charlotte Moss, Eirini Tsotra, Charalampos Gousis, Debra Josephs, Deborah Enting, Christina Karampera, Muhammad Khan, Jose Roca, Ailsa Sita-Lumsden, Kasia Owczarczyk, Harriet Wylie, Anna Haire, Daniel Smith, Kamarul Zaki, Angela Swampillai, Mary Lei, Vishal Manik, Vasiliki Michalarea, Rebecca KristeleitAnca Mera, Elinor Sawyer, Lucy Flanders, Irene De Francesco, Sophie Papa, Paul Ross, James Spicer, Bill Dann, Vikash Jogia, Nisha Shaunak, Hartmut Kristeleit, Anne Rigg, Ana Montes, Mieke Van Hemelrijck, Saoirse Dolly

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Background: This study aimed to assess the outcome of cancer patients undergoing systemic anti-cancer treatment (SACT) at our centre to help inform future clinical decision-making around SACT during the COVID-19 pandemic. Methods: Patients receiving at least one episode of SACT for solid tumours at Guy’s Cancer Centre between 1 March and 31 May 2020 and the same period in 2019 were included in the study. Data were collected on demographics, tumour type/stage, treatment type (chemotherapy, immunotherapy, biological-targeted) and SARS-CoV2 infection. Results: A total of 2120 patients received SACT in 2020, compared to 2449 in 2019 (13% decrease). From 2019 to 2020, there was an increase in stage IV disease (62% vs. 72%), decrease in chemotherapy (42% vs. 34%), increase in immunotherapy (6% vs. 10%), but similar rates of biologically targeted treatments (37% vs. 38%). There was a significant increase in 1st and 2nd line treatments in 2020 (68% vs. 81%; p < 0.0001) and reduction in 3rd and subsequent lines (26% vs. 15%; p = 0.004) compared to 2019. Of the 2020 cohort, 2% patients developed SARS-CoV2 infections. Conclusions: These real-world data from a tertiary Cancer Centre suggest that despite the challenges faced due to the COVID-19 pandemic, SACT was able to be continued without any significant effects on the mortality of solid-tumour patients. There was a low rate (2%) of SARS-CoV-2 infection which is comparable to the 1.4%-point prevalence in our total cancer population.

Original language	English
Article number	266
Journal	Cancers
Volume	14
Issue number	2
DOIs	https://doi.org/10.3390/cancers14020266
Publication status	Published - 1 Jan 2022

Keywords

COVID-19
Oncology
Systemic anti-cancer treatment

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers14020266

Cite this

Russell, B., Moss, C., Tsotra, E., Gousis, C., Josephs, D., Enting, D., Karampera, C., Khan, M., Roca, J., Sita-Lumsden, A., Owczarczyk, K., Wylie, H., Haire, A., Smith, D., Zaki, K., Swampillai, A., Lei, M., Manik, V., Michalarea, V., ... Dolly, S. (2022). The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer Centre. Cancers, 14(2), Article 266. https://doi.org/10.3390/cancers14020266

@article{42f863902a6d472cac166e4a2e547bef,

title = "The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy{\textquoteright}s Cancer Centre",

abstract = "Background: This study aimed to assess the outcome of cancer patients undergoing systemic anti-cancer treatment (SACT) at our centre to help inform future clinical decision-making around SACT during the COVID-19 pandemic. Methods: Patients receiving at least one episode of SACT for solid tumours at Guy{\textquoteright}s Cancer Centre between 1 March and 31 May 2020 and the same period in 2019 were included in the study. Data were collected on demographics, tumour type/stage, treatment type (chemotherapy, immunotherapy, biological-targeted) and SARS-CoV2 infection. Results: A total of 2120 patients received SACT in 2020, compared to 2449 in 2019 (13% decrease). From 2019 to 2020, there was an increase in stage IV disease (62% vs. 72%), decrease in chemotherapy (42% vs. 34%), increase in immunotherapy (6% vs. 10%), but similar rates of biologically targeted treatments (37% vs. 38%). There was a significant increase in 1st and 2nd line treatments in 2020 (68% vs. 81%; p < 0.0001) and reduction in 3rd and subsequent lines (26% vs. 15%; p = 0.004) compared to 2019. Of the 2020 cohort, 2% patients developed SARS-CoV2 infections. Conclusions: These real-world data from a tertiary Cancer Centre suggest that despite the challenges faced due to the COVID-19 pandemic, SACT was able to be continued without any significant effects on the mortality of solid-tumour patients. There was a low rate (2%) of SARS-CoV-2 infection which is comparable to the 1.4%-point prevalence in our total cancer population.",

keywords = "COVID-19, Oncology, Systemic anti-cancer treatment",

author = "Beth Russell and Charlotte Moss and Eirini Tsotra and Charalampos Gousis and Debra Josephs and Deborah Enting and Christina Karampera and Muhammad Khan and Jose Roca and Ailsa Sita-Lumsden and Kasia Owczarczyk and Harriet Wylie and Anna Haire and Daniel Smith and Kamarul Zaki and Angela Swampillai and Mary Lei and Vishal Manik and Vasiliki Michalarea and Rebecca Kristeleit and Anca Mera and Elinor Sawyer and Lucy Flanders and {De Francesco}, Irene and Sophie Papa and Paul Ross and James Spicer and Bill Dann and Vikash Jogia and Nisha Shaunak and Hartmut Kristeleit and Anne Rigg and Ana Montes and {Van Hemelrijck}, Mieke and Saoirse Dolly",

note = "Funding Information: Funding: This research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Guy{\textquoteright}s and St Thomas{\textquoteright} NHS Foundation Trust and King{\textquoteright}s College London (IS-BRC-1215-20006). The authors are solely responsible for study design, data collection, analysis, decision to publish, and preparation of the manuscript. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. We also acknowledge support from Cancer Research UK King{\textquoteright}s Health Partners Centre at King{\textquoteright}s College London and Guy{\textquoteright}s and St Thomas{\textquoteright} NHS Foundation Trust Charity Cancer Fund. Funding Information: This research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Guy?s and St Thomas? NHS Foundation Trust and King?s College London (IS-BRC-1215-20006). The authors are solely responsible for study design, data collection, analysis, decision to publish, and preparation of the manuscript. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. We also acknowledge support from Cancer Research UK King?s Health Partners Centre at King?s College London and Guy?s and St Thomas? NHS Foundation Trust Charity Cancer Fund. Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = jan,

day = "1",

doi = "10.3390/cancers14020266",

language = "English",

volume = "14",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "2",

}

Russell, B, Moss, C, Tsotra, E, Gousis, C, Josephs, D , Enting, D, Karampera, C, Khan, M, Roca, J, Sita-Lumsden, A, Owczarczyk, K, Wylie, H, Haire, A, Smith, D, Zaki, K, Swampillai, A, Lei, M, Manik, V, Michalarea, V, Kristeleit, R, Mera, A, Sawyer, E, Flanders, L, De Francesco, I, Papa, S, Ross, P, Spicer, J, Dann, B, Jogia, V, Shaunak, N, Kristeleit, H, Rigg, A, Montes, A, Van Hemelrijck, M & Dolly, S 2022, 'The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer Centre', Cancers, vol. 14, no. 2, 266. https://doi.org/10.3390/cancers14020266

TY - JOUR

T1 - The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer Centre

AU - Russell, Beth

AU - Moss, Charlotte

AU - Tsotra, Eirini

AU - Gousis, Charalampos

AU - Josephs, Debra

AU - Enting, Deborah

AU - Karampera, Christina

AU - Khan, Muhammad

AU - Roca, Jose

AU - Sita-Lumsden, Ailsa

AU - Owczarczyk, Kasia

AU - Wylie, Harriet

AU - Haire, Anna

AU - Smith, Daniel

AU - Zaki, Kamarul

AU - Swampillai, Angela

AU - Lei, Mary

AU - Manik, Vishal

AU - Michalarea, Vasiliki

AU - Kristeleit, Rebecca

AU - Mera, Anca

AU - Sawyer, Elinor

AU - Flanders, Lucy

AU - De Francesco, Irene

AU - Papa, Sophie

AU - Ross, Paul

AU - Spicer, James

AU - Dann, Bill

AU - Jogia, Vikash

AU - Shaunak, Nisha

AU - Kristeleit, Hartmut

AU - Rigg, Anne

AU - Montes, Ana

AU - Van Hemelrijck, Mieke

AU - Dolly, Saoirse

N1 - Funding Information: Funding: This research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London (IS-BRC-1215-20006). The authors are solely responsible for study design, data collection, analysis, decision to publish, and preparation of the manuscript. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. We also acknowledge support from Cancer Research UK King’s Health Partners Centre at King’s College London and Guy’s and St Thomas’ NHS Foundation Trust Charity Cancer Fund. Funding Information: This research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) based at Guy?s and St Thomas? NHS Foundation Trust and King?s College London (IS-BRC-1215-20006). The authors are solely responsible for study design, data collection, analysis, decision to publish, and preparation of the manuscript. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. We also acknowledge support from Cancer Research UK King?s Health Partners Centre at King?s College London and Guy?s and St Thomas? NHS Foundation Trust Charity Cancer Fund. Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Background: This study aimed to assess the outcome of cancer patients undergoing systemic anti-cancer treatment (SACT) at our centre to help inform future clinical decision-making around SACT during the COVID-19 pandemic. Methods: Patients receiving at least one episode of SACT for solid tumours at Guy’s Cancer Centre between 1 March and 31 May 2020 and the same period in 2019 were included in the study. Data were collected on demographics, tumour type/stage, treatment type (chemotherapy, immunotherapy, biological-targeted) and SARS-CoV2 infection. Results: A total of 2120 patients received SACT in 2020, compared to 2449 in 2019 (13% decrease). From 2019 to 2020, there was an increase in stage IV disease (62% vs. 72%), decrease in chemotherapy (42% vs. 34%), increase in immunotherapy (6% vs. 10%), but similar rates of biologically targeted treatments (37% vs. 38%). There was a significant increase in 1st and 2nd line treatments in 2020 (68% vs. 81%; p < 0.0001) and reduction in 3rd and subsequent lines (26% vs. 15%; p = 0.004) compared to 2019. Of the 2020 cohort, 2% patients developed SARS-CoV2 infections. Conclusions: These real-world data from a tertiary Cancer Centre suggest that despite the challenges faced due to the COVID-19 pandemic, SACT was able to be continued without any significant effects on the mortality of solid-tumour patients. There was a low rate (2%) of SARS-CoV-2 infection which is comparable to the 1.4%-point prevalence in our total cancer population.

AB - Background: This study aimed to assess the outcome of cancer patients undergoing systemic anti-cancer treatment (SACT) at our centre to help inform future clinical decision-making around SACT during the COVID-19 pandemic. Methods: Patients receiving at least one episode of SACT for solid tumours at Guy’s Cancer Centre between 1 March and 31 May 2020 and the same period in 2019 were included in the study. Data were collected on demographics, tumour type/stage, treatment type (chemotherapy, immunotherapy, biological-targeted) and SARS-CoV2 infection. Results: A total of 2120 patients received SACT in 2020, compared to 2449 in 2019 (13% decrease). From 2019 to 2020, there was an increase in stage IV disease (62% vs. 72%), decrease in chemotherapy (42% vs. 34%), increase in immunotherapy (6% vs. 10%), but similar rates of biologically targeted treatments (37% vs. 38%). There was a significant increase in 1st and 2nd line treatments in 2020 (68% vs. 81%; p < 0.0001) and reduction in 3rd and subsequent lines (26% vs. 15%; p = 0.004) compared to 2019. Of the 2020 cohort, 2% patients developed SARS-CoV2 infections. Conclusions: These real-world data from a tertiary Cancer Centre suggest that despite the challenges faced due to the COVID-19 pandemic, SACT was able to be continued without any significant effects on the mortality of solid-tumour patients. There was a low rate (2%) of SARS-CoV-2 infection which is comparable to the 1.4%-point prevalence in our total cancer population.

KW - COVID-19

KW - Oncology

KW - Systemic anti-cancer treatment

UR - http://www.scopus.com/inward/record.url?scp=85122179029&partnerID=8YFLogxK

U2 - 10.3390/cancers14020266

DO - 10.3390/cancers14020266

M3 - Article

AN - SCOPUS:85122179029

SN - 2072-6694

VL - 14

JO - Cancers

JF - Cancers

IS - 2

M1 - 266

ER -

The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer Centre

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this